HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
about
Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virusConsiderations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategiesEarly antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruptionImmune control of HIV-1 infection after therapy interruption: immediate versus deferred antiretroviral therapy.Antiretroviral treatment in HIV-infected infants and young children: novel issues raised by the Mississippi babyThe detection and management of early HIV infection: a clinical and public health emergency.Criticality of timing for anti-HIV therapy initiationTimely HAART initiation may pave the way for a better viral control.Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States.Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys.Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients.Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infectionControl of viral replication after cessation of HAARTDrug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South AfricaThe setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.Are there benefits to starting antiretroviral therapy during primary HIV infection? Conclusions from the Seattle Primary Infection Cohort vary by control groupOrigin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integrationThe size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruptionHIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation: HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent vBrief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials.Antiretroviral treatment interruption and loss to follow-up in two HIV cohorts in Australia and Asia: implications for 'test and treat' prevention strategy.Clinical management of acute HIV infection: best practice remains unknown.HIV eradication: combinatorial approaches to activate latent viruses.British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review).HIV-1 Eradication: Early Trials (and Tribulations).In Vivo Models of Human Immunodeficiency Virus Persistence and Cure Strategies.Socioeconomic and clinical factors explaining the risk of unstructured antiretroviral therapy interruptions among Kenyan adult patients.HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy.Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy.Nonhuman Primate Models for Studies of AIDS Virus Persistence During Suppressive Combination Antiretroviral Therapy.Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals.The pharmacological treatment of acute HIV infections in neonates.Age at antiretroviral therapy initiation and cell-associated HIV-1 DNA levels in HIV-1-infected children.British HIV Association guidelines for the management of HIV infection in pregnant women 2012
P2860
Q26797870-1BA96365-1A55-416C-A7DE-1F96EAB8F0DCQ26825814-A7BF50E9-B390-49A7-B0F9-B3D5AD70D74BQ28742727-F18C0F47-3417-4841-8493-FC2AC187AF9BQ33511372-76CCCDBB-AE1E-448C-9F22-F32EF9B1242CQ33557037-6D60DD02-686E-4AF5-85F0-739667A01562Q33586581-49F6C0CB-7CC0-4C07-87C9-21EA6EE42B8EQ33784494-72A300AC-ED17-4E37-A31B-BD310AA134DFQ33833189-6926256F-8E0B-47F9-B7DA-F66964EC595AQ33875036-B2535BB4-945A-48D3-9940-615102756CBBQ34020988-61F8855E-FCFF-4453-8CF4-7EFDE28F40EDQ34292622-DDAA0E75-A34F-43C9-8112-5DD4859E33BAQ34405543-B0EB7DD4-501D-46D3-A009-510D701CBE2BQ34615847-2E4E1196-4340-465D-AF08-DE9022FF46C1Q35217629-6D8C468B-4A00-4B27-8AAD-B5BF93F58AF4Q35623734-FD84D91C-86EE-4FAA-8838-E22F0DE3DA4AQ36136406-963CC859-998F-41D0-A852-C427CDB0E6B3Q36481572-3EA87BF2-5770-4610-A542-B2E9F77C766AQ36495526-6A3692A9-DED6-4ACE-A79F-6240EBD397D8Q36824388-E743C0A7-5276-47AE-9E38-30D364003015Q36864918-4FD5366D-565B-46A4-8CFC-D095EEB00D83Q37014116-6383ABE4-9C58-4EC9-A61D-B57B236EB838Q37404322-8C9314D9-C42A-4194-800B-1A2BBDC80EF7Q37789343-8CE1DB12-B06F-46ED-A6BF-F3424EC11AD6Q38271132-B0286454-09BE-485A-9ECB-0F1F88BBA7E5Q38325427-296E0818-5B89-4940-B57F-A478BA8AA99FQ38675631-B45457B0-4EDF-4E2D-9E8E-DB337ADBE8D9Q39315707-CFAA9EFB-4511-4767-A414-59CEFD132E37Q40023160-39A146D5-254E-4A41-A829-0E0F939BB1F4Q40240401-4C6E6935-F107-4105-97CE-2117577F6F83Q40250340-0366A9AF-FACB-4268-8BB5-ED54786E588FQ45326424-4DCB64B7-9626-40AA-B534-CB6211FE1DE0Q47555195-3DA0CA65-DBEE-4712-9FD6-19631356112DQ47591909-5F266781-2CEA-4FE8-97B7-B20CDBBF5937Q52591828-1E369601-F8BC-4944-8612-5D93FEC70C89Q57076282-11AC6526-EA4B-4146-846D-C008B711D693
P2860
HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
HIV-1 viral rebound dynamics a ...... active antiretroviral therapy.
@en
HIV-1 viral rebound dynamics a ...... active antiretroviral therapy.
@nl
type
label
HIV-1 viral rebound dynamics a ...... active antiretroviral therapy.
@en
HIV-1 viral rebound dynamics a ...... active antiretroviral therapy.
@nl
prefLabel
HIV-1 viral rebound dynamics a ...... active antiretroviral therapy.
@en
HIV-1 viral rebound dynamics a ...... active antiretroviral therapy.
@nl
P2093
P1433
P1476
HIV-1 viral rebound dynamics a ...... active antiretroviral therapy.
@en
P2093
Evian Fernandez Garcia
Frank Miedema
Hanneke Schuitemaker
Jan M Prins
Joep Ma Lange
Katalyn Pogány
Kees Brinkman
Radjin Steingrover
Suzanne Jurriaans
P304
P356
10.1097/QAD.0B013E328305BD77
P407
P577
2008-08-01T00:00:00Z